Why the study?
In rapidly evolving fields like Onco-Cardiology, real-world clinical evidence lags behind advances in cancer treatment, requiring expert opinion and dedicated guidelines tailored to clinical practices such as those in Japan.
This review outlines the current global standard of care for cancer-associated thrombosis using DOACs and LMWH, highlighting the urgent need for flexible, evidence-based guidelines in Japan where LMWH is not approved.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mikio Mukai (2023) conducted a review in Cancer-associated thrombosis (CAT) and cancer-associated venous thromboembolism (CAVTE). Direct oral anticoagulants (DOACs) and Low molecular weight heparin (LMWH) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: